FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

Peptide Library

AOD-9604

Anti-Obesity Drug 9604 / Tyr-hGH Fragment 177-191

Weight Loss & Metabolic

AOD-9604 is a synthetic peptide fragment corresponding to amino acids 177-191 of human growth hormone (hGH), modified with a tyrosine residue at the N-terminus. Developed by Metabolic Pharmaceuticals in Australia, it was designed to isolate the lipolytic (fat-burning) activity of hGH without its growth-promoting or diabetogenic effects. Despite failing Phase 2B clinical trials for obesity in 2007, it received TGA approval in Australia as a food-grade supplement and remains widely used in weight management research.

Mechanism of Action

Modified fragment of human growth hormone (amino acids 177-191). Stimulates lipolysis and inhibits lipogenesis without growth-promoting or diabetogenic effects.

Research Protocols

For research purposes only. Not medical advice.

Research protocols typically use 300-600mcg daily via subcutaneous injection, in the morning on empty stomach.

Research Notes

Clinical Research Status

AOD-9604 completed Phase 2B clinical trials for obesity conducted by Metabolic Pharmaceuticals, which failed to demonstrate statistically significant weight loss over placebo in a 24-week trial of 536 obese patients. The Australian TGA subsequently approved it with GRAS status for use in food products (2014), a controversial decision given the failed efficacy trials. It remains investigational for injectable use and is not FDA-approved for any indication.

Key Published Findings

Early studies in obese Zucker rats and mice demonstrated significant fat reduction without affecting IGF-1 levels or causing the insulin resistance associated with full-length hGH. The peptide stimulates lipolysis and inhibits lipogenesis through interaction with the beta-3 adrenergic receptor pathway. Human trial data showed that while some dose groups trended toward fat loss, the primary endpoint was not met, and the magnitude of effect did not justify further development as a standalone obesity drug.

Safety Profile

AOD-9604 demonstrated an excellent safety profile in clinical trials with no serious adverse events attributed to the drug and no effects on glucose metabolism, IGF-1, or other growth-related markers. Unlike full-length hGH, it does not cause insulin resistance, fluid retention, or joint pain. The fragment does not stimulate growth of bone, cartilage, or other tissues, confirming successful isolation of the lipolytic domain from growth-promoting activity.

Drug Interactions & Contraindications

No significant drug interactions have been documented in clinical trial data. Theoretical synergism exists with other lipolytic agents (beta-agonists, caffeine) though this has not been formally studied. No absolute contraindications have been identified beyond standard peptide precautions (pregnancy, active malignancy). The lack of IGF-1 stimulation means cancer-related contraindications applicable to GH secretagogues do not apply.

Comparison to Related Compounds

Unlike full-length hGH or GH secretagogues (GHRP-6, Ipamorelin, CJC-1295), AOD-9604 does not elevate GH or IGF-1 levels, meaning it cannot cause GH-related side effects but also cannot provide GH's anabolic, recovery, or anti-aging benefits. Compared to tirzepatide and semaglutide, its weight loss efficacy is substantially lower based on available trial data. FRAG 176-191 (without the tyrosine modification) is a related compound sometimes confused with AOD-9604.

Community Observations

Typically dosed at 250-500mcg subcutaneously daily, administered in the morning on an empty stomach to capitalize on fasted lipolysis. Often combined with other fat loss peptides or GH secretagogues to provide complementary mechanisms. Users report modest improvements in localized fat reduction over 8-12 week protocols, though expectations should be tempered by the failed Phase 2B trial results showing limited efficacy as a standalone agent.

Half Life

~30-45 minutes

Reconstitution

Bacteriostatic water (BAC)

Storage

Lyophilized

Refrigerate 2-8C up to 24 months.

Reconstituted

Refrigerate 2-8C. Use within 30 days.

US Legal Status

Research chemical (not FDA-approved)

Also Known As

Anti-Obesity Drug 9604Tyr-hGH Fragment 177-191

Frequently Asked Questions

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment corresponding to amino acids 177-191 of human growth hormone (hGH), modified with a tyrosine residue at the N-terminus. Developed by Metabolic Pharmaceuticals in Australia, it was designed to isolate the lipolytic (fat-burning) activity of hGH without its growth-promoting or diabetogenic effects. Despite failing Phase 2B clinical trials for obesity in 2007, it received TGA approval in Australia as a food-grade supplement and remains widely used in weight management research.

How does AOD-9604 work?

Modified fragment of human growth hormone (amino acids 177-191). Stimulates lipolysis and inhibits lipogenesis without growth-promoting or diabetogenic effects.

What is the US regulatory status of AOD-9604?

Research chemical (not FDA-approved)

What is the half-life of AOD-9604?

~30-45 minutes

What else is AOD-9604 called?

Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191

Peptide Contacts provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.

Read full disclaimer